Variation of NK, NKT, CD4⁺ T, CD8⁺ T cells, and IL-17A by CalliSpheres^® microspheres-transarterial chemoembolization in refractory liver metastases patients

References

• Horn SR, Stoltzfus KC, Lehrer EJ, et al. Epidemiology of liver metastases. Cancer Epidemiol. 2020;67:101760.
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Brodt P, Clavien PA, et al. Liver metastases. Nat Rev Dis Primers. 2021;7(1):27.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Aoki S, Yamashita H, Abe O, et al. Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review. Transl Cancer Res. 2020;9(8):5087–5095.
   PubMed Web of Science ®Google Scholar
• Datta J, Narayan RR, Kemeny NE, et al. Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review. JAMA Surg. 2019;154(8):768–776.
   PubMed Web of Science ®Google Scholar
• Li J, Wang N, Shi C, et al. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma. J Can Res Ther. 2021;17(3):733–739.
   PubMed Web of Science ®Google Scholar
• Zhao G, Liu S, Zhang Y, et al. Irinotecan eluting beads-transarterial chemoembolization using callispheres(R) microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases. Ir J Med Sci. 2022;191(3):1139–1145.
   PubMed Web of Science ®Google Scholar
• Zhang G, Tang R, Wu J, et al. Initial experience of drug-eluting bead transarterial chemoembolization with CalliSpheres((R)) microspheres in treating liver metastases patients. Transl Cancer Res. 2020;9(3):1630–1639.
   PubMed Web of Science ®Google Scholar
• Chang X, Sun P, Zhang J, et al. CalliSpheres drug-eluting beads transarterial-chemoembolization in the treatment of liver metastases from breast cancer: Initial experience in 14 patients. Medicine (Baltimore). 2021;100(52):e28407.
   PubMed Web of Science ®Google Scholar
• Yin L, Chen L, Qi Z, et al. Gene expression-based immune infiltration analyses of liver cancer and their associations with survival outcomes. Cancer Genet. 2021;254-255:75–81.
   PubMed Web of Science ®Google Scholar
• Kamiya T, Chang YH, Campana D. Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. Cancer Immunol Res. 2016;4(7):574–581.
   PubMed Web of Science ®Google Scholar
• Polidoro MA, Mikulak J, Cazzetta V, et al. Tumor microenvironment in primary liver tumors: a challenging role of natural killer cells. World J Gastroenterol. 2020;26(33):4900–4918.
   PubMed Web of Science ®Google Scholar
• Liao R, Sun J, Wu H, et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2013;32(1):3.
   PubMedGoogle Scholar
• Ren Z, Yue Y, Zhang Y, et al. Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles. Front Immunol. 2021;12:624789.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Lee S, Lee HH, et al. Korean red ginseng enhances immunotherapeutic effects of NK cells via eosinophils in metastatic liver cancer model. Nutrients. 2021;14(1):134.
   PubMed Web of Science ®Google Scholar
• Fu J, Zhang Z, Zhou L, et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology. 2013;58(1):139–149.
   PubMed Web of Science ®Google Scholar
• Sun C, Xu J, Song J, et al. The predictive value of Centre tumour CD8(+) T cells in patients with hepatocellular carcinoma: comparison with immunoscore. Oncotarget. 2015;6(34):35602–35615.
   PubMedGoogle Scholar
• Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012;35(5):980–985.
   PubMed Web of Science ®Google Scholar
• Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8(10):1982–1989.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
   PubMed Web of Science ®Google Scholar
• Xie M, Li N, Xu X, et al. The efficacy of PD-1/PD-L1 inhibitors in patients with liver metastasis of Non-Small cell lung cancer: a Real-World study. Cancers (Basel. 2022;14(17):4333.
   PubMed Web of Science ®Google Scholar
• Zhou M, Liu B, Shen J. Immunotherapy for hepatocellular carcinoma. Clin Exp Med. 2022 Aug 24. Epub ahead of print.
   Web of Science ®Google Scholar
• Liu L, Sun H, Wu S, et al. IL17A promotes CXCR2dependent angiogenesis in a mouse model of liver cancer. Mol Med Rep. 2019;20:1065–1074.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cheng G, Chen H, et al. IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma. CH. 2021;77(1):37–47.
   Google Scholar
• Kee JY, Ito A, Hojo S, et al. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. Oncol Rep. 2013;29(3):975–982.
   PubMed Web of Science ®Google Scholar
• Dai Z, Wang Z, Lei K, et al. Irreversible electroporation induces CD8(+) T cell immune response against post-ablation hepatocellular carcinoma growth. Cancer Lett. 2021;503:1–10.
   PubMed Web of Science ®Google Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253–257.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Murray SM, Forner A, et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9(9):e003311.
   PubMed Web of Science ®Google Scholar
• Liao J, Xiao J, Zhou Y, et al. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol Med Rep. 2015;12(4):6065–6071.
   PubMed Web of Science ®Google Scholar
• Feng M, Li G, Qian X, et al. IL-17A-producing NK cells were implicated in liver injury induced by ischemia and reperfusion. Int Immunopharmacol. 2012;13(2):135–140.
   PubMed Web of Science ®Google Scholar
• Wang X, Sun R, Hao X, et al. IL-17 constrains natural killer cell activity by restraining IL-15-driven cell maturation via SOCS3. Proc Natl Acad Sci U S A. 2019;116(35):17409–17418.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao XY. Transcription factors associated with IL-15 cytokine signaling during NK cell development. Front Immunol. 2021;12:610789.
   PubMed Web of Science ®Google Scholar
• Byrne EM, Llorian-Salvador M, Tang M, et al. IL-17A damages the Blood-Retinal barrier through activating the janus kinase 1 pathway. Biomedicines. 2021;9(7):831.
   PubMed Web of Science ®Google Scholar
• Gao Y, Guo J, Bao X, et al. Adoptive transfer of autologous invariant natural killer T cells as immunotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Oncologist. 2021;26(11):e1919–e1930.
   PubMed Web of Science ®Google Scholar